The complete laboratory reference for tirzepatide — how dual incretin agonism works, what the SURPASS and SURMOUNT programs reported, and how to verify a research batch.
Tirzepatide was the first dual GIP/GLP-1 receptor agonist to reach the market, and it reset expectations for what a single peptide could do in metabolic research. For laboratories, it is also one of the most analytically well-documented peptides available — which makes it an ideal case study in how modern incretin engineering works.
Structural engineering
Tirzepatide is a 39-amino-acid linear peptide built on the glucose-dependent insulinotropic polypeptide (GIP) backbone. Three modifications define it: substitutions that confer GLP-1 receptor activity, an aminoisobutyric acid (Aib) residue that blocks DPP-4 degradation, and a C20 fatty diacid chain linked through a hydrophilic spacer at lysine 20. The fatty acid chain binds serum albumin reversibly, stretching the circulating half-life to roughly five days and enabling once-weekly dosing in published protocols.
Why dual agonism outperformed single agonism
GLP-1 receptor signaling reduces appetite and slows gastric emptying. GIP receptor signaling, once considered metabolically uninteresting, appears to enhance insulin sensitivity and modulate how adipose tissue stores and releases lipid. The SURMOUNT-1 trial quantified the result: a mean body-weight reduction of approximately 21% at the 15 mg dose over 72 weeks, versus roughly 3% on placebo — numbers that exceeded every prior pharmacological obesity trial.
The trial landscape at a glance
| Program | Population | Headline Finding |
|---|---|---|
| SURPASS (1–5) | Type 2 diabetes | Superior HbA1c and weight reduction vs. comparators |
| SURMOUNT-1 | Obesity, non-diabetic | ~21% mean weight loss at 15 mg / 72 weeks |
| SURMOUNT-5 | Obesity, head-to-head | Outperformed semaglutide 2.4 mg on mean weight loss |
| SUMMIT | HFpEF with obesity | Reduced composite heart-failure outcomes |
Verification standards for research material
- HPLC purity ≥98% with the chromatogram available on request
- LC-MS confirming the average mass near 4,813.5 Da
- Counterion (acetate or TFA) content quantified
- Endotoxin testing for any batch destined for cell-culture work
- A lot number on the vial that matches the COA exactly
Is tirzepatide the same as semaglutide?
No. Semaglutide activates only the GLP-1 receptor. Tirzepatide is a dual GIP/GLP-1 agonist with a different sequence, mass, and pharmacological profile.
Why does tirzepatide have a fatty acid attached?
The C20 fatty diacid binds albumin in solution, shielding the peptide from rapid renal clearance and extending its half-life to about five days.
How should lyophilized tirzepatide be stored?
Frozen at -20°C or below, protected from light and moisture, in a sealed vial. Avoid repeated freeze-thaw after reconstitution.
